PARP inhibitors in breast cancer

Area of Science:

• Oncology
• Cancer Therapeutics
• DNA Repair Mechanisms

Background:

• DNA damage is a cornerstone of cancer therapy, utilized in chemotherapy and radiotherapy.
• Poly (ADP-Ribose) polymerase (PARP) inhibitors represent a novel class of targeted therapeutics.
• PARP inhibitors exploit DNA repair defects for cancer treatment.

Purpose of the Study:

• To review the clinical development of PARP inhibitors in breast cancer.
• To highlight ongoing clinical trials involving PARP inhibitors.
• To discuss critical outstanding questions for optimizing PARP inhibitor strategies.

Main Methods:

• Review of existing clinical data and ongoing trials of PARP inhibitors in breast cancer.
• Analysis of preliminary clinical activity of PARP inhibitors as single agents and in combination therapy.
• Commentary on unresolved issues in the field of PARP inhibition for breast cancer.

Main Results:

• PARP inhibitors demonstrate preliminary clinical activity in BRCA mutation-associated breast cancer.
• Combination of PARP inhibitors with chemotherapy shows promise in triple-negative breast cancer.
• Widespread enthusiasm exists for rapid clinical development of these novel agents.

Conclusions:

• PARP inhibitors are a rapidly developing therapeutic class for breast cancer.
• Optimal use of PARP inhibitors requires further understanding and investigation.
• Addressing key questions is critical for successful PARP inhibitor-based strategies in all stages of breast cancer.